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Besides several changes in HAART were needed due to resistance or 
persisting replication. After the last change in HAART (darunavir-
ritonavir),voriconazole C0 decreased to 0.25 mg/L (50% decrease). 
Eventually, ranitidine was replaced by esomeprazole 40 mg IV BID. 
Three days later, voriconazole C0 increased 14-fold and voricona-
zole dose could be reduced by 50% to 100 mg (2.5 mg/kg) BID. 
There were no other medication changes. Subsequent voriconazole 
C0 stayed within the therapeutic range.
Results: Voriconazole systemic exposure depends on various factors 
among which CYP 450 activity influenced by genetic polymorphisms 
and DDI. Our patient was heterozygous for the CYP2C19*17 variant 
allele, which has been associated with lower voriconazole AUC com-
pared with wild-type individuals. However, her phenotype indicated 
a reduced activity of CYP2C19.
The change in voriconazole concentrations cannot be explained 
by a DDI with another drug of the antiretroviral treatment.
Conclusion: We report the case of an HIV patient with disseminated 
fungal disease who achieved targeted voriconazole C0 using esome-
prazole as a “booster” to overcome an ultrarapid CYP2C19*17/*1 
genotype and a treatment by a CYP2C19 inducer such as ritonavir. 
Further evaluation is warranted for this "boosting strategy" to define 
the right booster dose, the relevance of this effect in rapid metaboliz-
ers and eventually transferability in clinical setting.
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Introduction: Acamprosate, a homo-taurine analogue, is approved 
for treatment of alcohol dependence. Meta-analyses favor acampro-
sate for its ability to support abstinence, which is the most stable type 
of remission in alcoholics. Yet, only a limited number of treatment-
seeking alcoholics use acamprosate, most likely because of individual 
differences in response and the lack of response predictors.
Patients (or Materials) and Methods: We used a pharmacometabo-
lomics approach to investigate metabolic response in serum amino acid 
metabolites (including acamprosate) between responders and nonre-
sponders to acamprosate treatment. Serum samples were collected 
before and after 3 months of acamprosate treatment. Efficacy was 
defined by self-reported abstinence during acamprosate treatment and 
average γ -glutamyl transferase (GGT) levels at baseline and 3-month 
follow-up were used to confirm abstinence. Of those, 14 responders and 
18 nonresponders comprised an investigation cohort and an additional 
30 responders and 28 nonresponders comprised a replication sample.
Results: Initial metabolite screening was conducted using 32 alco-
hol-dependent subjects. Glutamate levels were significantly higher at 
baseline in the 14 responders compared with the 18 nonresponders 
[t(30) = 2.7, P < 0.05]. After acamprosate treatment, serum glu-
tamate levels in the responder group significantly decreased com-
pared with baseline [t(26) = 3.3, P < 0.05). Similarly, in a replication 
sample of 58 additional alcohol-dependent subjects, responders had 
significantly higher glutamate levels at baseline compared with the 
nonresponder group [t(88) = 2.8, P < 0.05], which decreased signifi-
cantly after acamprosate treatment [t(86) = 3.6, P < 0.05].
Conclusion: Our findings suggest that high glutamate levels may 
be a biomarker to predict the efficacy of acamprosate treatment in 
alcohol-dependent subjects.
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Introduction: Tolperisone, a centrally acting muscle relaxant, is 
used for relieving spasticity of neurological origin and muscle spasm 
associated with painful locomotor diseases. Tolperisone is mainly 
metaolized by CYP2D6 and CYP2C19, CYP1A2, and CYP2B6 are 
also involved in the metabolism of tolperisone. CY2D6 is responsible 
for variablility of drug response, largely due to genetic polymor-
phism. Therefore, we investigated the effects of CYP2D6 genetic 
polymorphism on the pharmacokinetics of tolperisone.
Patients (or Materials) and Methods: Thirty healthy Korean subjects 
were selected and they were divided into 3 different groups according 
to CYP2D6 genotype, CYP2D6*wt/*wt (*wt= *1 or *2, n = 10), 
CYP2D6*wt/*10 (n = 10) and CYP2D6*10/*10 (n = 10). After 
overnight fasting, each subject received a single 150-mg oral dose of 
tolperisone. Blood samples were collected up to 12 hours after drug 
intake, and plasma concentrations of tolperisone were determined 
by using LC-MS/MS analytical system.
Results: Cmax and AUCinf of tolperisone in CYP2D6*10/*10 geno-
type group was significantly higher than those in CYP2D6*wt/*wt 
group (P = 0.0007 and P = 0.0002, respectively). Apparent oral clear-
ance (CL/F) of tolperisone in CYP2D6*wt/*10 and CYP2D6*10/*10 
group was 64% and 75% lower than that in CYP2D6*wt/*wt group 
(P < 0.001 and P = 0.0001, respectively). Among 3 genotypes, differ-
ences in t1/2 of tolperisone were not statistically significant.
Conclusion: Tolperisone is mainly metabolized by CYP2D6 and 
CYP2D6 genetic polymorphism has a significant impact on the phar-
macokinetics of tolperisone.
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Introduction: Human multidrug and toxin extrusion 1 
(hMATE1/SLC47A1) transporter may be involved in the active 
elimination clearance of many cationic drugs in the kidneys. Scarcity 
of knowledge about endogenous substrates of hMATE1 appears to 
hinder exploration of the roles of genetic polymorphisms on the func-
tional activity of hMATE1.
Patients (or Materials) and Methods: Fifty-four healthy volunteers 
(32 males and 22 females; 23 [2] years) underwent 3-hour timed-
urine collection and blood drawing at the midpoint. Plasma and 
urinary levels of N1-methylnicotinamide (MNA) and creatinine 
were measured with a liquid chromatography-mass spectrometry 
system. Renal tubular secretion clearance of MNA (CLTS,MNA) was 
calculated by subtracting the renal clearance of creatinine (a sub-
stitution of glomerular filtration rate) from that of MNA. Genetic 
variants of hMATE1/SLC47A1 and another renal cation transporter, 
hOCT2/SLC22A2, were genotyped by polymerase chain reaction 
followed by direct sequencing. The protocol of the present study was 
